|
|
 |
 |
| |
 Printable version |
Acute lymphoblastic leukemia with Philadelphia chromosome : treatment with kinase inhibitors |
Bulletin du Cancer. Volume 94, Number 10, 871-80, Octobre 2007, Synthèse
|
 Résumé
Article gratuit
|
Author(s) : Xavier Thomas |
Summary : Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches. In Philadelphia chromosome-positive ALL, the optimal treatment requires the addition of BCR-ABL tyrosine kinase inhibitors, as imatinib. Despite advances, the outcome remains poor, and novel agents are desperately required. The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) ALL has prompted the development of second-generation compounds active against mutant forms, including dasatinib and nilotinib. |
Keywords : acute lymphoblastic leukemia, Philadelphia chromosome, imatinib, dasatinib, nilotinib, resistance, mutations, Bcr-Abl |
|
